Low-intensity electric-field Rx boosts chemo in NSCLC
Patients with advanced non-small-cell lung cancer achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to their chemotherapy. In a single-arm, phase II study, physicians delivered TTF therapy, using the NovoTTF-100L from Novocure, to 42 patients with stage IIIb-IV metastatic NSCLC who had failed prior treatments. Patients in the study received TTF therapy for 12 hours a day in combination with pemetrexed (Alimta) every three weeks until disease progression.
Patients with advanced non-small-cell lung cancer achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to their chemotherapy. In a single-arm, phase II study, physicians delivered TTF therapy, using the NovoTTF-100L from Novocure, to 42 patients with stage IIIb-IV metastatic NSCLC who had failed prior treatments. Patients in the study received TTF therapy for 12 hours a day in combination with pemetrexed (Alimta) every three weeks until disease progression. TTF therapy slows and reverses tumor cell proliferation by inhibiting mitosis. Patients treated with TTF plus pemetrexed had a median overall survival time of 13.8 months compared with 8.3 months reported for pemetrexed alone. The one-year survival rate for the combination was 57% vs 30% reported for pemetrexed alone (ESMO 2010 abstract 371PD).
Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy
November 24th 2024In observance of Alzheimer Disease Awareness Month, held annually in November, we took a look back at the past year's news and expert insights in cell and gene therapy for Alzheimer disease.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
